Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised FACT-Finder on its acquisition of real-time AI-personalization vendor Loop54
Mandate

Vinge advised FACT-Finder on its acquisition of real-time AI-personalization vendor Loop54

November 11, 2021 M&A Intellectual Property Commercial Agreements Employment and Benefits

Vinge advised FACT-Finder on its acquisition of real-time AI-personalization vendor Loop54 making it one of the first major consolidations of leading e-commerce SaaS solutions in search, merch and personalization.

The merging of their proprietary algorithms will enable FACT-Finder customers to provide digital experiences that are unlike any other on the market and further expand FACT-Finder's international presence.

Vinge’s team consisted of responsible partner Matthias Pannier and associates Vilhelm Rondahl, Gustav Persson, Ebba Nyberg (M&A), Isabell Nielsen, Karl-Gustaw Tobola, Karolina Fuhrmann (Commercial Agreements/IT), Sofia Bergenstråhle (Intellectual Property), Carl Östlund (Employment), Karl-Hugo Engdahl (GDPR) and Ulf Pyk (Real Estate).

 

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026